Eloxx Pharmaceuticals, Inc. (ELOX) SEC Filing 10-Q Quarterly report for the period ending Saturday, June 30, 2018

PDFPDF Microsoft WordWord Microsoft ExcelExcel SubscribeRSS E-mailEmail Smartphone and TabletMobile last10k.com/sec-filings/elox/0001564590-18-021183.htm

 

Exhibit 99.1

 

 

Eloxx Pharmaceuticals Reports Second Quarter 2018 Financial and Operating Results and Provides Business Update

 

CTA approved in Belgium and IND open in the U.S. for investigational drug candidate, ELX-02

 

On track to initiate Phase 2 clinical trials in cystic fibrosis and cystinosis in 2018

 

Expanded Leadership Team with Global Pharmaceutical Executives to Accelerate Growth

 

Company to host webcast and conference call on Tuesday, August 7, 2018 at 4:30 pm ET

 

Waltham, MA. – August 7, 2018 – Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis and other diseases caused by nonsense mutations limiting production of functional proteins, today reported its financial results for the three and six months ended June 30, 2018 and provided a business update.

 

“We are pleased to have achieved important regulatory milestones in Europe and the U.S. gaining clearance to initiate two Phase 2 clinical trials for our lead investigational product candidate, ELX-02, in cystic fibrosis and cystinosis, respectively. We are on track to initiate these this year and we are funded through data readouts,” said Robert E. Ward, Chairman and CEO of Eloxx Pharmaceuticals. “I am very gratified to have been successful in attracting experienced pharmaceutical executives to our leadership team who I am confident will add significant value as we build a high-performance culture committed to maximizing the value of ELX-02 and our library of novel compounds and pursue global collaborations.”

 

Recent Accomplishments

 

·Eloxx’s CTA for ELX-02 in cystic fibrosis has been approved by the Federal Agency for Medicines and Health Products (the “FAMHP”) in Brussels, Belgium. The European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN) has reviewed and approved our protocol for a Phase 2 clinical trial of ELX-02 in cystic fibrosis patients with a G542X mutation and has given it “high priority” status. We expect to initiate this trial in the fourth quarter of 2018.

 


The following information was filed by Eloxx Pharmaceuticals, Inc. on Tuesday, August 7, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

 Please wait while we load the requested 10-Q Quarterly Report. If it does not load, please click the link below:

 https://www.last10k.com/sec-filings/report/1035354/000156459018021183/elox-10q_20180630.htm

Companies may provide additional information to their SEC Filings as exhibits. Click a link below to view an exhibit that was filed with this report:

Exhibit 10.6 - MATERIAL CONTRACT

 Please wait while we load the requested exhibit. If it does not load, please click the link below:

 https://www.last10k.com/sec-filings/report/1035354/000156459018021183/elox-ex106_216.htm
Exhibit 31.1 - RULE 13A-14A/15D-14A CERTIFICATION

 Please wait while we load the requested exhibit. If it does not load, please click the link below:

 https://www.last10k.com/sec-filings/report/1035354/000156459018021183/elox-ex311_9.htm
Exhibit 31.2 - RULE 13A-14A/15D-14A CERTIFICATION

 Please wait while we load the requested exhibit. If it does not load, please click the link below:

 https://www.last10k.com/sec-filings/report/1035354/000156459018021183/elox-ex312_8.htm
Exhibit 32.1 - SECTION 1350 CERTIFICATION

 Please wait while we load the requested exhibit. If it does not load, please click the link below:

 https://www.last10k.com/sec-filings/report/1035354/000156459018021183/elox-ex321_7.htm
Exhibit 32.2 - SECTION 1350 CERTIFICATION

 Please wait while we load the requested exhibit. If it does not load, please click the link below:

 https://www.last10k.com/sec-filings/report/1035354/000156459018021183/elox-ex322_6.htm
  • Form Type: Quarterly
  • Number of times amended: 0
  • Accession Number: 0001564590-18-021183
  • Submitted to the SEC: Friday, August 10, 2018 6:06:03 AM EST
  • Accepted by the SEC: Friday, August 10, 2018
  • Period ending: June 2018
  • Industry: Commercial Physical And Biological Research